Drug Profile
ORG 101
Alternative Names: Acne vulgaris vaccine - Origimm; ORG101; ORI-001; ORI-A-ce001Latest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Origimm
- Class Antiacnes; Skin disorder therapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Acne vulgaris
Most Recent Events
- 27 Nov 2023 Sanofi Pasteur completes a phase I trial in Acne vulgaris in Germany (IM) (NCT05131373)
- 02 Dec 2021 Phase-I clinical trials in Acne vulgaris (Prevention) in Germany (unspecified route) (Origimm company website, December 2021)
- 01 Dec 2021 Origimm has been acquired by Sanofi